Life Science Investing U.S. Food and Drug Administration Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Life Science Investing Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Life Science Investing Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
Life Science Investing Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Life Science Investing Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Life Science Investing Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference
Life Science Investing Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Life Science Investing Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Life Science Investing Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Life Science Investing Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
Life Science Investing Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
Forge Resources Intersects 3.4 g/t Gold over 44.75 Metres, and 800 Metre Step-Out Discovers 1.04 g/t Gold over 55.52 Metres at Alotta, Yukon
Element79 Gold Corp Files NI 43-101 Technical Report for Elephant Project in Nevada's Battle Mountain District
